Lopinavir: Clinical Trials

66 trials of Lopinavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

49 completed, 9 unknown, 4 terminated, 2 recruiting. 66 Phase 3, 13 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 366Completed 49, Unknown 9, Terminated 4, Recruiting 2, Withdrawn 2
Phase 213Completed 7, Unknown 4, Terminated 2

Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir

Trials (filtered) newest first · largest first

All 66 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment
Phase 2 / Phase 3CompletedANRS, Emerging Infectious Diseases2942020-11-272024-12-27
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Hydroxychloroquine Sulfate Tablets, Lopinavir/ Ritonavir Oral Tablet, Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets - COVID-19, Coronavirus Infection
Phase 3UnknownCardresearch19682020-06-032021-01-26
Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
Baricitinib - Pharmacological Action
Phase 2 / Phase 3UnknownHospital of Prato2002020-05-162020-04-22
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab - COVID
Phase 3WithdrawnFondation Hôpital Saint-Joseph2020-05-072021-04-27
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland
Lopinavir/ritonavir - Prevention of COVID-19
Phase 3CompletedCalmy Alexandra3262020-04-232021-04-12
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Favipiravir, Standard of Care - COVID-19
Phase 2 / Phase 3UnknownChromis LLC3302020-04-232020-06-16
COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir
Lopinavir/ritonavir - Coronavirus Infections, Post-exposure Prophylaxis
Phase 3UnknownUnity Health Toronto1232020-04-172021-12-14
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19
Phase 2 / Phase 3UnknownMedical University of Vienna5002020-04-162021-03-02
Treatment for COVID-19 in High-Risk Adult Outpatients
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin - COVID-19, SARS-CoV-2
Phase 2 / Phase 3TerminatedUniversity of Washington2892020-04-162022-08-08
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19
Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine - COVID-19
Phase 2 / Phase 3UnknownFasa University of Medical Sciences302020-04-042020-04-13
Trial of Treatments for COVID-19 in Hospitalized Adults
Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A - Corona Virus Infection
Phase 3CompletedInstitut National de la Santé Et de la Recherche Médicale, France15522020-03-222026-07-08
Randomised Evaluation of COVID-19 Therapy
Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine - Pneumonia
Phase 3RecruitingUniversity of Oxford700002020-03-192026-04-21
Baricitinib Therapy in COVID-19
Baricitinib 4 MG Oral Tablet - COVID, Pneumonia
Phase 2 / Phase 3CompletedFabrizio Cantini122020-03-162020-04-24
Evaluation of Low-dose Darunavir in a Switch Study
Darunavir, Lopinavir - HIV Infections
Phase 3CompletedWillem Daniel Francois Venter3002016-06-302018-06-26
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic)
Phase 3RecruitingUMC Utrecht200002016-04-112026-11-04
First-Line Treatment for HIV-2
Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir - HIV-2 Infection
Phase 2 / Phase 3CompletedANRS, Emerging Infectious Diseases2102016-01-262019-07-22
Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
Raltegravir, Lopinavir/Ritonavir - HIV, Pregnancy
Phase 2 / Phase 3TerminatedFundação Bahiana de Infectologia332015-06-012024-10-15
Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy
triple therapy, dual therapy - HIV
Phase 3CompletedUniversity Hospital, Tours2242014-12-012025-12-26
Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults
cART(TDF/AZT+3TC+LPV/r), CTL infusion - Acute HIV Infection
Phase 3UnknownYongtao Sun, MD, PhD652014-08-012018-04-26
Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection
Triplitode, Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir - AIDS/HIV PROBLEM
Phase 3UnknownPeking Union Medical College182014-07-012014-08-19

Showing 20 of 66. Sign in to see all of them.

Conditions studied

HIV Infections (36)  ·  COVID-19 (12)  ·  Acquired Immunodeficiency Syndrome (9)  ·  Pneumonia (4)  ·  Breast Feeding (3)  ·  Coronavirus Infections (3)  ·  Community-Acquired Pneumonia (2)  ·  Malaria (2)  ·  Virus Diseases (2)  ·  HIV Seropositivity (1)  ·  Immune System Diseases (1)  ·  Immunologic Deficiency Syndromes (1)  ·  Infections (1)  ·  Influenza, Human (1)  ·  Lentivirus Infections (1)

Sponsors

Abbott (9)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (8)  ·  ANRS, Emerging Infectious Diseases (5)  ·  Bristol-Myers Squibb (4)  ·  French National Agency for Research on AIDS and Viral Hepatitis (4)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (2)  ·  GlaxoSmithKline (2)  ·  University of California, San Francisco (2)  ·  Bamrasnaradura Infectious Diseases Institute (1)  ·  Calmy Alexandra (1)  ·  Cardresearch (1)  ·  Centers for Disease Control and Prevention (1)  ·  Chromis LLC (1)  ·  Columbia University (1)  ·  Fabrizio Cantini (1)

Countries

United States (21)  ·  France (18)  ·  South Africa (14)  ·  Canada (11)  ·  Spain (11)  ·  Brazil (10)  ·  Italy (9)  ·  Puerto Rico (9)  ·  Germany (8)  ·  United Kingdom (8)  ·  Australia (7)  ·  Thailand (7)  ·  Belgium (6)  ·  India (5)  ·  Malawi (5)

Top investigators

Grant Dorsey, MD, PhD (2)  ·  Thomas J Podsadecki, MD (2)  ·  Adrien Sawadogo, MD (1)  ·  Alberto M La Rosa, MD (1)  ·  Alexandra Calmy (1)  ·  Alexandra Calmy, Prof (1)  ·  Andrew D. Hull, MD (1)  ·  Ann C Collier, MD (1)  ·  Anna Maria Geretti, MD, PhD (1)  ·  Avy Violari, MBChB, FCPSA (1)  ·  Bernd Jilma, MD (1)  ·  Carlos Brites, MD, PhD (1)  ·  Charles van der Horst, MD (1)  ·  Chipepo Kankasa, MD (1)

Results publications

PMID 34473343, PMID 29767684, PMID 33394942, PMID 37489818, PMID 1783744, PMID 18190257, PMID 18480202, PMID 19020325, PMID 19417580, PMID 19682100, PMID 20074791, PMID 20418798, PMID 20554982, PMID 20571601, PMID 20843990, PMID 20871389, PMID 20942666, PMID 21134574, PMID 21548986, PMID 21767103, PMID 21777076, PMID 21876053, PMID 22029910, PMID 22123685, PMID 22155918, PMID 22180523, PMID 22301417, PMID 22509297, PMID 22541418, PMID 22649265, PMID 22713768, PMID 22719231, PMID 22730929, PMID 22734817, PMID 22879899, PMID 23039034, PMID 23059199, PMID 23165467, PMID 23190222, PMID 23276808, PMID 23358639, PMID 23468553, PMID 23700341, PMID 23764539, PMID 23766338, PMID 23924639, PMID 24038035, PMID 24135775, PMID 24209829, PMID 24326597

NIH funding

2005 (2), U01AI068636 (2), 2008 (1), 2009 (1), 2015 (1), 2023 (1), 5UM1AI068634 (1), P01HD059454 (1), R01AI062512 (1), R01HD061255 (1)